The integration of anti-p53 antibody-based targeted therapy with PD-L1 immune checkpoint inhibitors will inaugurate a novel chapter in the therapeutic paradigm for patients afflicted with DLBCL. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.